When it comes to the question of which biotech companies could be the next M&A targets, one analyst cited in today’s article says the “easy answer” is oncology companies, as […]
read more
What Does “Merger Monday” Mean For Biotech?
“I believe that with the evidence of yesterday’s mergers, specifically the astoundingly well-priced purchase of Immunomedics (IMMU) by Gilead, that this is an area that should be speculated upon. Biotech’s […]
read more